Summary
This phase 2 randomised controlled trial, published in The Lancet Gastroenterology & Hepatology (2023), investigated semaglutide 2·4 mg once weekly as a therapeutic intervention in patients with cirrhosis secondary to non-alcoholic steatohepatitis. As a GLP-1 receptor agonist, semaglutide was evaluated for its potential to improve hepatic fibrosis and related outcomes in an advanced liver disease population, representing a pharmacological approach to a condition historically lacking disease-modifying treatments.
UK applicability
The findings are directly applicable to United Kingdom clinical practice, as NASH and metabolic dysfunction-associated fatty liver disease are significant health burdens in the UK population. Approval and uptake would depend on National Institute for Health and Care Excellence (NICE) assessment and integration into NHS pathways for advanced liver disease management.
Key measures
Hepatic fibrosis stage, inflammation markers, liver-related outcomes, and adverse events in NASH-cirrhosis patients treated with semaglutide versus placebo
Outcomes reported
The study evaluated the efficacy and safety of semaglutide 2·4 mg weekly versus placebo in patients with advanced non-alcoholic steatohepatitis (NASH)-related cirrhosis. Outcome measures likely included markers of liver fibrosis, hepatic inflammation, and histological resolution of advanced liver disease.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.